In patients undergoing percutaneous coronary intervention (PCI), intensifying antiplatelet therapy based on platelet reactivity testing reduces cardiovascular mortality and stent thrombosis, according ...
Use of platelet function testing during dual antiplatelet therapy, including a P2Y12 antagonist, in acute coronary syndromes does not improve clinical outcomes. Researchers at King's College London ...
November 10, 2011 (San Francisco, California)— Investigators who explored platelet-function testing for guiding antiplatelet therapy in a low-risk PCI population, who earlier this year had announced ...
Barcelona, Spain, 31 August: Studies from a growing body of convincing data show that responsiveness to antiplatelet therapy is real. This is a clinically important issue and there is a need to ...
HOUSTON--(BUSINESS WIRE)--Houston-based Aggredyne, Inc., a biomedical diagnostics company widely recognized as a leader in the field of platelet function testing, has appointed Dr. Jeffrey Dahlen as ...
Controversy regarding a possible role of proton pump inhibitors (PPIs) in interfering with the efficacy of dual antiplatelet therapy continues with a new study showing that pantoprazole—thought to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback